Agios Pharmaceuticals Inc (AGIO) 35.54 $AGIO
Why Agios Pharmaceuticals Inc. Shares Flopped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Agios Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:30AM CDT
--Three First-in-Class Compounds now in Clinical Development
Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.
Multiple Insiders of Agios Pharmaceuticals, Inc. (AGIO)-Nasdaq bought Shares of AGIO
M2 - Thu May 01, 9:05AM CDT
Reported by InsiderCow.com at 2014-04-30 16:02:19 ET
Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014
Business Wire - Wed Apr 30, 3:02PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, May 8, 2014, at 8:30 a.m. EDT to report its first quarter 2014 financial results and discuss recent business activities.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:49AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session, reversing the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
Biotech Breakouts: How to Trade Agios Pharma
at The Street - Thu Apr 24, 5:47AM CDT
This heavily shorted biotech stock could be setting up to trigger a major breakout trade.
Agios Pharmaceuticals prices public offering of 2m common shares
M2 - Thu Apr 24, 4:29AM CDT
Novel drugs company Agios Pharmaceuticals (NasdaqGS:AGIO) stated on Wednesday that it has priced a public offering of 2,000,000 shares of its common stock.
Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Business Wire - Wed Apr 23, 5:56PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $44.00 per share, before underwriting discounts. All of the shares in the offering are to be sold by Agios. In addition, Agios has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less the underwriting discount.
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 22, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Agios Pharmaceuticals announces public offering of 2m common shares
M2 - Tue Apr 22, 4:54AM CDT
Novel drugs company Agios Pharmaceuticals (NasdaqGS:AGIO) reported on Monday that it has begun an underwritten public offering of 2,000,000 shares of its common stock.
Biotech Investing 101: What Investors Need to Know About Phase 1 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Clinical trials are huge milestones in drug development, and the success or failure of the whole company can hinge on the outcome of a single trial. The odds are generally against any given drug, as many more drugs fail in clinical trials than...
Agios Pharmaceuticals Announces Proposed Offering of Common Stock
Business Wire - Mon Apr 21, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. All of the shares in the offering are to be sold by Agios. Agios intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock sold in the offering. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Business Wire - Thu Apr 17, 7:01AM CDT
--- Third Agios Program to Enter Clinic in Less than a Year -
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Agios Taps Wall Street Off Early Data, Aims For $75M
Ben Fidler, The Motley Fool - Motley Fool - Thu Apr 10, 8:53AM CDT
Agios Pharmaceuticals gave investors its first glimpse of encouraging, but early human clinical data a few days ago, and saw its shares soar as a result. Now, it's looking to cash in. Cambridge, MA-based Agios wants to raise up to $75 million...
Why Agios Pharmaceuticals Inc. Shares Flopped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:08PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agios Pharmaceuticals , a clinical-stage...
Agios Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:30AM CDT
--Three First-in-Class Compounds now in Clinical Development
Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.
Multiple Insiders of Agios Pharmaceuticals, Inc. (AGIO)-Nasdaq bought Shares of AGIO
M2 - Thu May 01, 9:05AM CDT
Reported by InsiderCow.com at 2014-04-30 16:02:19 ET
Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014
Business Wire - Wed Apr 30, 3:02PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, May 8, 2014, at 8:30 a.m. EDT to report its first quarter 2014 financial results and discuss recent business activities.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:49AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session, reversing the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
Biotech Breakouts: How to Trade Agios Pharma
at The Street - Thu Apr 24, 5:47AM CDT
This heavily shorted biotech stock could be setting up to trigger a major breakout trade.
Agios Pharmaceuticals prices public offering of 2m common shares
M2 - Thu Apr 24, 4:29AM CDT
Novel drugs company Agios Pharmaceuticals (NasdaqGS:AGIO) stated on Wednesday that it has priced a public offering of 2,000,000 shares of its common stock.
Agios Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Business Wire - Wed Apr 23, 5:56PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $44.00 per share, before underwriting discounts. All of the shares in the offering are to be sold by Agios. In addition, Agios has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less the underwriting discount.
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 22, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Agios Pharmaceuticals announces public offering of 2m common shares
M2 - Tue Apr 22, 4:54AM CDT
Novel drugs company Agios Pharmaceuticals (NasdaqGS:AGIO) reported on Monday that it has begun an underwritten public offering of 2,000,000 shares of its common stock.
Biotech Investing 101: What Investors Need to Know About Phase 1 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Clinical trials are huge milestones in drug development, and the success or failure of the whole company can hinge on the outcome of a single trial. The odds are generally against any given drug, as many more drugs fail in clinical trials than...
Agios Pharmaceuticals Announces Proposed Offering of Common Stock
Business Wire - Mon Apr 21, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. All of the shares in the offering are to be sold by Agios. Agios intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock sold in the offering. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
Business Wire - Thu Apr 17, 7:01AM CDT
--- Third Agios Program to Enter Clinic in Less than a Year -
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Agios Taps Wall Street Off Early Data, Aims For $75M
Ben Fidler, The Motley Fool - Motley Fool - Thu Apr 10, 8:53AM CDT
Agios Pharmaceuticals gave investors its first glimpse of encouraging, but early human clinical data a few days ago, and saw its shares soar as a result. Now, it's looking to cash in. Cambridge, MA-based Agios wants to raise up to $75 million...
